Oxford, UK – OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, has been honoured with a spot on the Financial Times’ prestigious ‘UK Best Employers 2025’ list. The Financial Times' UK Best Employers list is compiled annually through a rigorous process that involves a detailed analysis of company practices, employee surveys, and external data from hundreds of companies across the UK. "We are thrilled to be recognised by the Financial Times as one of the UK’s best employers," said Julie Copperthwaite, Head of Group HR Operations at OXB. For more information about OXB and their impact on gene and cell therapy, please visit http://www.oxb.com. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types.

Source: The Times March 13, 2025 11:55 UTC